HOME >> BIOLOGY >> NEWS
Common virus may contribute to uncommon bone disease in children

A common virus may play a major role in causing a painful disease of immune cells that attacks children's bones, according to a new study. The research may eventually lead to an easier diagnosis and to more effective treatments of the disease, Langerhans cell histiocytosis.

Researchers found evidence of the virus, human herpesvirus 6 (HHV-6) in the tissues of 25 of 35 children with Langerhans cell histiocytosis (LCH), compared to virus detected in only five of 19 children without LCH. The research team, led by John P. Dormans, M.D., director of Orthopaedic Surgery at The Children's Hospital of Philadelphia, published its findings in the January/February issue of the Journal of Pediatric Orthopaedics.

Langerhans cells, found in the blood, play an active role in the immune system. An uncontrolled excess of Langerhans cells leads to LCH, with effects that range from a limited, spontaneously resolving illness to a chronic, life-threatening disease involving multiple organ systems. Although rare, occurring in approximately five children per million, LCH most commonly strikes bone, causing painful lesions or fractures.

"LCH is called the 'great imitator' because it resembles particular bone cancers," said Dr. Dormans. "Fortunately, most children survive the disease these days." Most bone lesions resolve on their own without treatment. In other cases, surgeons successfully treat the disease by removing the abnormal area of bone.

However, successful treatment may elude physicians when LCH is chronic and affects multiple systems. Chemotherapy may succeed, at least temporarily, but only for 50 to 60 percent of patients. The cause of LCH remains unknown, and the Children's Hospital researchers investigated its origins, with the goal of advancing treatments.

"It's important to define whether LCH is primarily a tumor-like process or a reactive process, that is, one in which the immune system reacts to an infection or other insult," said M
'"/>

Contact: Joey Marie McCool
McCool@email.chop.edu
267-426-6070
Children's Hospital of Philadelphia
8-Mar-2004


Page: 1 2

Related biology news :

1. Common cold virus can cause polio in mice when injected into muscles
2. Common call for action on European Research Council (ERC)
3. Common therapy for HIV associated with cervical abnormality regression
4. Common chemicals morphing into potential toxins in Arctic
5. Common worm provides insights into salmonella virulence
6. Common airborne substance makes asthmatics more sensitive to house dust mites: study
7. Common genetic damages in non-dividing cells lead to the creation of mutant proteins
8. Common nutrients fed to pregnant mice altered their offsprings coat color
9. Common treatment for depression is safe and effective for Alzheimers patients
10. Common gene variant increases risk of atherosclerosis
11. Common thyroid cancer gene mutation found

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/5/2020)... , ... March 05, 2020 , ... ... a strategic partnership agreement with Phoenestra GmbH to accelerate Cytonus’ existing products and ... in San Diego, California. Phoenestra is a biotech company located in Austria. ...
(Date:3/5/2020)... , ... March 05, 2020 , ... Patients in need ... dental implants from Dr. Nickelice Brand of Dental Implants of Ocala. Same-day dental ... get an entirely new smile in just one day. This treatment utilizes advanced technology ...
(Date:3/5/2020)... BOSTON (PRWEB) , ... March 05, 2020 , ... ... its AlphaSTEM Test™ technology . The AlphaSTEM Test™ is the first, ... tissue stem cells. Other technologies that attempt to provide information about the ...
Breaking Biology News(10 mins):
(Date:3/10/2020)... ... 2020 , ... Ortho Clinical Diagnostics, a global leader of in vitro diagnostics ... ID-MTS, a suite of extended antigen in a gel testing format used for blood ... and ORTHO VISION® Max in the United States and Canada. The clearances allow testing ...
(Date:3/4/2020)... ... March 04, 2020 , ... ... and services, today announced the launch of its FleXpress™ high-throughput recombinant antibody ... number of antibodies at 80 ml scale. All production occurs in Absolute ...
(Date:3/3/2020)... ... March 03, 2020 , ... Ideal Implant Incorporated ... breast implant technology at the IMCAS Innovation Shark Tank 2020 in Paris, France ... plastic surgery, and aesthetic science industries that promise to revolutionize medical practices in ...
(Date:2/26/2020)... ... February 25, 2020 , ... Continuing its leading ... the results of its safety assessment on the biotechnologically produced 3-Fucolsyllactose (3-FL) HMO. ... milk. These complex carbohydrates are indigestible and therefore function as a prebiotic by ...
Breaking Biology Technology:
Cached News: